AstraZeneca (LON:AZN) Receives “Buy” Rating from Berenberg Bank

AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by equities researchers at Berenberg Bank in a research note issued to investors on Friday,London Stock Exchange reports. They presently have a GBX 140 ($1.86) price target on the biopharmaceutical company’s stock. Berenberg Bank’s target price suggests a potential downside of 98.64% from the company’s current price.

AZN has been the topic of several other research reports. JPMorgan Chase & Co. reissued an “overweight” rating on shares of AstraZeneca in a report on Wednesday, February 19th. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a research note on Tuesday, April 29th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of GBX 6,303.50 ($83.82).

AstraZeneca Price Performance

Shares of LON AZN traded up GBX 62 ($0.82) during mid-day trading on Friday, reaching £102.92 ($136.86). The company’s stock had a trading volume of 231,190,938 shares, compared to its average volume of 18,542,689. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. AstraZeneca has a 52 week low of GBX 9,573.51 ($127.31) and a 52 week high of £133.88 ($178.03). The stock has a fifty day moving average of £107.21 and a two-hundred day moving average of £108.62. The firm has a market capitalization of £198.02 billion, a PE ratio of 28.21, a P/E/G ratio of 0.86 and a beta of 0.17.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.